VINCERX PHARMA
We derive our name from the latin word vincēre meaning
“to conquer”.
We aspire to conquer cancer with innovative therapies.

Our Vision

To address the unmet medical needs of our patients with paradigm-shifting therapeutics.

Clinical
Program

VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer.

Clinical
Program

VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer.

Pipeline

VINCERX PHARMA
NEWS

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain on track for 2H2023 and

Menu